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Abstract
The advent of triple therapy (TT) with first-generation protease inhibitors boceprevir (BOC) and telaprevir (TVR) in
addition to pegylated interferon and ribavirin resulted in a significant gain in terms of sustained virological
response (SVR) when treating naive or previous treated patients with genotype 1 (G1) chronic hepatitis C (CHC).
This gain is partly balanced by the increased complexity of treatment and by the raised costs and risks of therapy,
making necessary to optimize the indication to TT.
Specifically, the identification of patient needing to TT over DT, the choice of the more correct therapeutic
approach according to baseline and on treatment SVR predictors, and the timing of antiviral treatment, appear key
issues to evaluate when considering TVR or BOC-based therapies.
Along this line, further efforts aimed to optimize the current TT regimens are still needed, especially in under-
represented groups of patients in phase 3 studies such as those with cirrhosis, where post-marketing data are
giving interesting evidences.
Introduction
In the last few years the treatment picture of patients with
genotype 1 (G1) chronic hepatitis C (CHC) is in rapid evo-
lution, due to the discovery of direct acting antiviral
(DAA) agents, to be used in combination with PEG-IFN
and RBV dual therapy (DT). Specifically, telaprevir (TVR)
and boceprevir (BOC), two nonstructural serine (NS3/4)
protease inhibitors, are the first DAAs approved for use in
the United States and European Union, although many
others are in the pipeline [1]. Interestingly the combina-
tion of TVR or BOC with PEG-IFN, and RBV (triple ther-
apy - TT) significantly increases the rate of SVR not only
in naive [2-4], but also in experienced [5-7] G1 CHC
patients. Specifically, when considering previous untreated
G1 CHC patients, phase 3 RCTs of TT with BOC
(SPRINT-2) [2] or TVR (ADVANCE and ILLUMINATE)
[3,4], showed SVR rates ranging from 63% to 75%, there-
fore highlighting, compared to DT, a gain in SVR rate of
about 25%. Similarly, phase 3 trials using TT with BOC
(RESPOND-2 and PROVIDE) [5,6] or TVR (REALIZE) (7)
and performed on previous treated G1 CHC patients,
showed that SVR rates progressively increased from 75% -
86% in relapser (RR), to 52% - 57% in partial responder
(PR) and further to 31% - 37% in null responder (NR),
resulting in a gain in terms of SVR, compared to DT, of
about 55%, 40% and 30%, respectively. Interestingly, it is
noteworthy to underline that BOC-based strategies always
include an initial 4 weeks lead-in phase with DT followed
by TT for a variable treatment duration of both PEG-IFN
plus RBV and BOC; by contrast TVR-based strategies
always include TT for 12 weeks followed by a variable DT
duration, with the possibility to use a lead-in phase only
for previous treated patients.
Although these results are very encouraging, the use of
these new drugs in clinical practice needs to be carefully
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evaluated because of such factors as the tolerability pro-
file, the issue of drug-drug interaction, the induction of
viral mutations of uncertain significance, and high costs.
With these limitations, it appears very relevant not only
to identify patients needing TT, but also to use the more
correct therapeutic approach and the best timing of
treatment.
Whom to treat?
The use of TT-based strategies in previous untreated or
previous treated G1 CHC patients implies a relevant
investment in terms of medical and economic resources,
also leading during treatment to a significant impairment
of the quality of life of the patient. Along this line, to avoid
or reduce lack of resources and useless sufferance of the
patients, it is very relevant to identify patients who could
be advantaged from TT.
When considering a previous untreated G1 CHC
patients, firstly it is very relevant to evaluate if the patient
is a candidate to antiviral therapy, and more to TT. In this
line in fact it is well accepted that antiviral treatment is
indicated in all G1 CHC patients with moderate or
advanced fibrosis (METAVIR score F2-F3-F4), evaluating
individually the indication for treatment of patients with
mild fibrosis (METAVIR score F0-F1) according to the
likelihood of disease progression [8,9]. However, after eval-
uating indication to treatment, the next step lies in the
attribution to DT versus TT. In this line different litera-
ture data showed that naive G1 CHC patients without
severe hepatic fibrosis and with IL28B CC genotype have a
likelihood of SVR greater than 80% when treated with DT,
being similar high rates of SVR also observed in patients
achieving a rapid virological response (RVR) (5% of
patients with IL28B TT/TC, and 30% of patients with
IL28B CC), regardless of the IL28B genotype [10]. There-
fore, due to the similar SVR rates observed in IL28BCC
naive patients underwent TVR (90%) or BOC-based (80%)
TT, it is possible to suggest to avoid TT in these sub-
groups of patients, due to the fact that the only advantage
presented by the TT compared to the DT is a potential
shortening of the treatment time in spite of higher costs
and higher side effects.
According to all the above, in an era in which resource
scarcity will be a prominent issue, we tested, in naïve G1
CHC patients, the cost-efficacy of a combined therapeutic
approach (DT and TT) compared to TT in all patients
[11]. In line with the above quoted data we observed that,
compared with a universal treatment with HCV PI of all
untreated G1 CHC patients, using selective treatment
strategies guided by RVR for BOC-based therapies, or
IL28B genotype for TVR-based strategies, we are able to
avoid exposure to HCV PI in 25-33% of patients, reducing
costs and risks, and improving benefits [11]. Figure 1
summarized cost-effectiveness of combined and universal
strategies compared to DT in naïve G1 CHC patients.
Therefore, we recommend using PI-free strategies as
first-line therapy in non-cirrhotic patients with IL28B CC
genotype or in those who achieve RVR, demanding the
use of BOC or TVR-based TT in all the other.
While in naïve G1 CHC patients, IL28B status and
RVR achievement are able to identify patients where DT
is not inferior to TT in terms of SVR, no DT easy-to-
treat sub-groups of previous treated patients were iden-
tified. Therefore, in this clinical setting, retreatment of
RR or nonresponder to DT is not recommended [8,9],
while a rational use of TT is suggested.
How to treat?
Therapeutic strategies using BOC or TVR are very com-
plex, differ between previous untreated and previous trea-
ted patients, differ among these groups according to on
treatment response and profile of previous response to
DT, and have been further complicated by discrepancies
between strategies tested in RCTs and strategies recom-
mended by EMA. Along this line, Figure 2A and 2B show
EMA recommendations for treatment of both naïve and
experienced G1 CHC patients with BOC and TVR-based
strategies, respectively.
In this complex picture, key issues are: a correct
assumption of DDAs; the possibility to shorten treat-
ment in a great proportion of patients; correct applica-
tion of stopping rules; a complete knowledge of factors
influencing the achievement of SVR.
A correct taking of DDAs is crucial to maintain a high
efficacy of treatment [12,13], minimizing the risk of viral
resistance to DAAs. In particular both DAAs, (especially
TVR) must be taken with a fat meal of at least 20 g that
favours DAAs absorption, and specifically TVR 375 mg
Figure 1 Drug costs (in 2011 euros) and effectiveness evaluated as
sustained virologic response. Each symbol represents drug costs versus
the proportion of patients who achieve SVR among the competing
strategies. (See, Cammà C, et al. Hepatology 2012;56:850-860).
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tablet must be dosed as 2 pills, 3 times a day, 7–9 hours
apart [14], and, similarly, boceprevir 200 mg capsules as
4 pills, 3 times a day, 7–9 hours apart [15].
A very relevant information arising from registrative
trials is that treatment can be shortened in a great
proportion of patients without compromising the effec-
tiveness of therapy. RCTs on naïve patients [2-4]
observed that patients achieving an extended rapid viro-
logical response (eRVR), defined as negative HCV-RNA
at week 8 maintained through to week 24 for BOC, and
Figure 2 Therapeutic schedules and stopping rules of telaprevir (A) and boceprevir (B) based therapies according to EMA recommendations.
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as negative HCV-RNA at week 4 maintained through to
week 12 for TVR, obtained SVR in more than 90% of
cases also reducing treatment duration to 24 and 28
weeks in TVR and BOC-based therapies respectively.
These data are of further interest in terms of cost-
efficacy and reduction of side-effects related to treat-
ment, if we considered that an eRVR was observed in
44% of patients of SPRINT-2 RCT [2], and in 54% and
63% of ADVANCE [3] and ILLUMINATE [4] studies
respectively. Interestingly, in BOC-related therapy,
SPRINT-1 study showed the utility of a lead-in phase in
increasing the rate of patients achieving an eRVR (62%
vs. 38%), finally increasing the number of patients who
may benefit from a shortened treatment [16]. Also in pre-
vious treated patients there is the possibility to shorten
treatment duration. Specifically, only RESPOND-2 study
[5] tested this hypothesis showing that patients with an
eRVR (46%) receiving 32 weeks of TT after the lead-in
phase had an SVR of 86%, similar to the 88% observed in
those with eRVR who received additional 12 weeks of
DT. However these results, not applicable to patients
with severe fibrosis, were not considered by EMA that
suggests a 48 weeks therapy also in previous treated
patients with eRVR [17]. By contrast, even if a shortened
treatment duration was not assessed in REALIZE RCT
[7], EMA, following post-hoc analyses of sub-group of
patients, suggests to shorten treatment to 24 weeks
(12 TT and 12 DT) in RR patients with eRVR [18]. As
well as in naïve patients, this recommendation could
have relevant management impact considering that eRVR
was obtained in 65.5% of RR patients directly treated
with TT, and in 87.2% of those treated with a lead-in
phase followed by TT. According to all the above a cor-
rect evaluation of eRVR is crucial for the optimization of
therapy in G1 CHC patients underwent TT. To stress
this issue and to give a practice message for clinical prac-
tice, a recent post-hoc analysis of RCTs of BOC and TVR
investigated the clinical relevance of on treatment detect-
able but below the assay lower limit of quantitation
(detectable/BLOQ) HCV RNA, with respect to undetect-
able HCV RNA [19]. This study clearly demonstrated
that, as performed in RCTs, undetectable HCV RNA
must be used to assess the eligibility to a shortened treat-
ment regimen, being detectable/BLOQ associated with a
reduction of SVR rates of about 20% compared to
patients with undetectable HCV RNA [19].
The early identification of patients without realistic like-
lihood of SVR to TT is another key issue when treating
CHC patients, in order to minimize risk of side-effects,
viral resistance and reduce useful costs. Considering TVR,
phase 3 studies established as stopping rules HCV RNA
levels > 1000 IU/mL at week 4, and a drop by <2 log10 at
week 12 (stop all drugs) for naïve patients [3,4]; and HCV
RNA levels > 100 IU/mL at weeks 4, 6, and 8, or a drop
<2 log10 at week 12 for previous treated patients [7]. Not-
withstanding these data, a re-analysis of EMA, based on
few cases of patients with HCV RNA at weeks 4 and 12
between 100 and 1000 IU/mL and achieving SVR, recom-
mended to stopping therapy in both naive and experi-
enced G1 CHC patients treated with TVR if HCV RNA
>1000 at week 4 (stop only TVR) or at week 12 (stop all
drugs) [18]. Instead AISF Italian guidelines maintained a
more conservative approach in experienced patients, sug-
gesting to use the cut-off of 100 IU/mL [20]. Considering
BOC, SPRINT-2 [2] and RESPOND-2 [5] studies recom-
mended to stop therapy in case of detectable HCV RNA
at week 24 in naive and at week 12 in previous treated G1
CHC patients. As well as with TVR, also for BOC, accord-
ing to post-hoc analyses of RCTs, EMA modified stopping
rules suggesting to stop therapy in case of HCV RNA
>100 IU/mL at week 12 in both naive and experienced
patients [17]. The rational of this recommendation was
also object of a recent scientific paper, aimed to identify
uniform stopping rules for all BOC-treated patients [21]
for both naive and experienced patients.
The last key issue in the use of TT, is the knowledge of
SVR predictors. Considering naïve patients, SPRINT-2 [2]
for BOC, and ADVANCE [3] for TVR, showed that the
severity of liver fibrosis and IL28B single nucleotide poly-
morphisms (SNP) affect treatment outcome also in
patients underwent TT. In addition, other factors nega-
tively affecting SVR were subtype 1a of viral genotype and
black race for both BOC and TVR-based therapies. For a
better evaluation of SVR predictors in naïve patients
underwent BOC-based TT, a post-hoc analysis has been
recently published, including in the model also IL28B
SNP, not evaluated by protocol in phase 3 trials. Interest-
ingly, this post-hoc analysis identified in baseline low HCV
viral load (≤400,000 IU/mL), IL28B rs 12979860 CC geno-
type, absence of cirrhosis, HCV genotype 1b, and non
black race as independent positive predictors of SVR [22].
In addition, Poordad and colleagues [22], considering data
of RCTs on the role of 1log10 HCV RNA drop after 4
weeks of DT as predictor of SVR among BOC-treated
patients, included in the model of SVR also this variable.
Interestingly, the author observed that HCV RNA drop
remained significantly associated with SVR, being loosed
the effect of IL28B genotype [22]. Considering previous
treated G1 CHC patients, data from RESPOND-2 [5] and
REALIZE [7] RCTs unequivocally showed that the pattern
of the previous response to DT strongly affects the likeli-
hood to achieve SVR after TT, with a progressive increase
in SVR rates from NR, to PAR and further to RR. Not-
withstanding the pattern of previous response to DT has a
great impact on SVR rates in case of retreatment with TT,
due to the low availability of these data in all patients in
clinical practice, it should be very useful to dispose of on
treatment predictors of response to TT. Along this line,
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data from the lead-in arm of REALIZE [7], and from
RESPOND-2 [5], considering together all previously trea-
ted G1 CHC patients, showed significantly lower SVR
rates in patients with HCV RNA drop <1log10 after
4 weeks of DT (33% for TVR, and 34% for BOC), com-
pared to those with a drop >1log10 (82% for TVR, and 79%
for BOC). In the evaluation of predictors of response to
TT among previous treated G1 CHC patients other signif-
icant factor needing to be evaluated are the severity of
liver fibrosis, and, even if at a les extent, the sub-type of
viral genotype, but not IL28B genotype. A further contri-
bution to the evaluation of SVR predictors in previous
treated patients, arises from the above quoted post-hoc
analysis of Poordad and colleagues [22] on data of
RESPOND-2 RCT. In this analysis, after correction for
genetic (IL28B), clinical-metabolic, viral and histological
variables, the pattern of previous response only, remained
independently associated with SVR after BOC-base TT
[22]. When adding in the model the 1log10 drop HCV
RNA at week 4, this last, together with the pattern of
response to previous DT, was also an independent predic-
tor [22].
When to treat?
In the above quoted sections of this review we showed
that TT approach adds benefits in terms of SVR in a great
proportion of naive G1 CHC patients, and in all previous
treated G1 CHC patients. In addition, we also showed that
TT was cost-effective compared to DT in both the two
groups of patients.
However, it is difficult to translate these data to the con-
clusion that all G1 CHC patients must be immediately
treated with BOC or TVR-based TT, being this issue
derived from both economic and clinical considerations.
From an economic point of view, in an era in which
resource scarcity is and will be a prominent issue, it is not
conceivable that all patients are treated with TT, consider-
ing the increase in costs due to HCV PI. Along this line,
other than to identify patients needing TT with respect to
DT (see above), it appears relevant to identify, according
to SVR predictors, patients where a treatment is needed in
a short time and with a high likelihood of SVR, from
patients where the treatment could be deferred and at low
likelihood of SVR. In this ongoing debated issue, the 2011
update of the practice guidelines by the American Associa-
tion of the Study of Liver Disease on Hepatitis C [9] does
not recommend any selective allocation of patients to TT
with first generation HCV PI. In our opinion, in order to
both optimize treatment and reduce risks, two extreme
examples could be considered (Figure 3): on one side
there are patients with previous RR with advanced CHC/
cirrhosis, that are a group of subjects at high risk of liver-
related morbidity and mortality in a short time, but also at
very high likelihood of SVR if treated with TT; on the
other side there are patients with a previous NR and with
minimal liver damage, that are a group where liver disease
progression is expected after a long time, and at low likeli-
hood of SVR, and therefore where more efficacious drugs
are awaited. This can also allow to reduce risk of viral
resistances potentially affecting the efficacy of future thera-
pies. Although these two examples are simple, also in
these cases some problems exist. In fact, considering the
first case, cirrhotic patients are underexpressed in RCTs,
and therefore data on efficacy and in particular on safety
Figure 3 Clinical scenarios where triple therapy or a wait-and-see strategy could be used.
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need to be confirmed. Along this line, ad interim data on
expanded access programs [23] of TVR and BOC in
patients with advanced HCV liver disease, are showing
rates of serious adverse events much higher compared to
those reported in RCTs. In addition, in patients with mini-
mal liver damage, the choice to defer antiviral treatment
discussed individually with the patients, could be imperfect
being the proposed scenarios limited by errors in diagnos-
ing liver damage and predicting progression of fibrosis, by
changes in the profile of the patient limiting availability
and tolerability of future therapies, and, finally by potential
pitfalls of the new drugs in development [24].
In addition, in the middle of these two cases, a great
grey area exists, where different factors could affect
SVR achievement, and where pros and cons of TT
should be carefully evaluated and discussed with the
individual patient. Along this line, the availability of
individual data from RCTs could allow a more cost-
efficacy use of TT.
Conclusions
RCTs and post-hoc analyses on TVR or BOC-based
therapies for naïve or previous treated G1 CHC patients
demonstrated a benefit of TT compared to DT. How-
ever due the complexity and the high rate of toxicity of
these new therapeutic strategies it is crucial to optimize
the best candidates to therapy, the best therapeutic
schedules, and the more correct timing of treatment. In
this line we suggest:
1) To rationally discriminate among naïve G1 CHC
patients who could benefit from DT (IL28BCC and/or
RVR patients), from those where TT is needed and
effective (RR patients), and from those who should await
new and more potent drugs (NR patients without signif-
icant liver damage).
2) To establish, according to baseline and on treat-
ment SVR predictors, the therapeutic schedule to be
applied in the individual patient, to achieve the best
results, reducing when possible treatment duration,
costs and risks.
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